Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance.

J Clin Invest 2019 Dec;129(12):5553-5567

Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA.

Immune checkpoint inhibitors (ICIs), although promising, have variable benefit in head and neck cancer (HNC). We noted that tumor galectin-1 (Gal1) levels were inversely correlated with treatment response and survival in patients with HNC who were treated with ICIs. Using multiple HNC mouse models, we show that tumor-secreted Gal1 mediates immune evasion by preventing T cell migration into the tumor. Mechanistically, Gal1 reprograms the tumor endothelium to upregulate cell-surface programmed death ligand 1 (PD-L1) and galectin-9. Using genetic and pharmacological approaches, we show that Gal1 blockade increases intratumoral T cell infiltration, leading to a better response to anti-PD1 therapy with or without radiotherapy. Our study reveals the function of Gal1 in transforming the tumor endothelium into an immune-suppressive barrier and that its inhibition synergizes with ICIs.

Download full-text PDF

Source
http://dx.doi.org/10.1172/JCI129025DOI Listing
December 2019

Publication Analysis

Top Keywords

tumor endothelium
12
gal1
5
tumor
5
gal1 reprograms
4
mechanistically gal1
4
migration tumor
4
reprograms tumor
4
tumor mechanistically
4
cell migration
4
programmed death
4
death ligand
4
cell-surface programmed
4
upregulate cell-surface
4
ligand pd-l1
4
endothelium upregulate
4
evasion preventing
4
multiple hnc
4
hnc mouse
4
icis multiple
4
treated icis
4

References

(Supplied by CrossRef)

Similar Publications